Technology evaluation: MRA, Chugai.
Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
Ding
Changhai
C
Menzies Centre for Population Health Research, University of Tasmania, 17 Liverpool Street, Hobart, 7000 TAS, Australia. changhai.ding@utas.edu.au
Jones
Graeme
G
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000628:therapy; D005871:Castleman Disease / Q000628:therapy; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000628:therapy; D006801:Humans; D015850:Interleukin-6 / Q000502:physiology; D009101:Multiple Myeloma / Q000628:therapy; D019947:Receptors, Interleukin-6 / Q000737:chemistry / Q000276:immunology*; D013673:Technology Assessment, Biomedical
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; C502936:tocilizumab